Waldencast Acquisition (WALD) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Waldencast plc reported a robust Q3 2024 performance with a 34.6% jump in comparable net revenue, driven by strong demand for its Obagi Medical and Milk Makeup brands. The company’s adjusted EBITDA surged by 134% compared to the previous year, reflecting strategic brand enhancements and operational efficiencies. Despite facing significant non-recurring costs, Waldencast maintained healthy cash conversion, supported by effective capital management.
For further insights into WALD stock, check out TipRanks’ Stock Analysis page.
